Earnings Labs

Sangamo Therapeutics, Inc. (SGMO)

Q1 2013 Earnings Call· Thu, May 9, 2013

$0.19

-7.24%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

+3.30%

1 Week

-2.59%

1 Month

-3.66%

vs S&P

-3.79%

Transcript

Ying Huang

Management

Okay. Good afternoon, everybody. My name is Ying Huang, I am the [inaudible] here at Barclays. Our next presenting company is Sangamo BioSciences. And I'm very pleased to introduce Edward Lanphier, the President and CEO of the company. With that, let me turn over the podium to Ed.

Edward Lanphier

Management

Thank you very much. It's a pleasure to be here. My presentation will contain forward-looking statements. I refer you to our Forms 10-K and 10-Q and particularly our recently filed 10-K. So for those of you new to the story, the single most important thing to remember about Sangamo and if you walk out of this room with nothing else, is our core technology is significantly different, absolutely unique compared to any other company in biotech. We have the ability to engineer a naturally occurring class of proteins. Proteins whose normal function it is to bind to DNA. And we can engineer these in a way that we can cause them to target exactly the DNA sequence we choose and use that ability to drive biology, to change the expression of a gene or to physically change the DNA sequence. So it's an incredibly powerful and quite frankly, very proprietary technology platform that we at Sangamo are using to develop novel drugs. And it's important to emphasize that strategic focus. We're not just trying to develop an incremental improvement, we're actually developing a new modality that at the end of the day, it isn't intend to get a better treatment, it's actually intended to drive genetic cures. And I'll be talking specifically about that strategy and why the technology platform permits that as we go through the presentation. But I think those are two key critical points; a highly differentiated technology platform and our goal is not just incremental improvements and therapeutics but actually genetic cures. We've also been very successful in leveraging the same core technology outside of human therapeutics DNA and plants has the same as DNA and rat for humans or [inaudible] and I'll talk about that. But it has allowed us to operate the company in…